| Identification | Back Directory | [Name]
4(3H)-Quinazolinone, 7-[(1-acetyl-4-piperidinyl)methoxy]-5-fluoro-2-[[(tetrahydro-2H-pyran-4-yl)thio]methyl]- | [CAS]
2360853-16-1 | [Synonyms]
4(3H)-Quinazolinone, 7-[(1-acetyl-4-piperidinyl)methoxy]-5-fluoro-2-[[(tetrahydro-2H-pyran-4-yl)thio]methyl]- | [Molecular Formula]
C22H28FN3O4S | [MOL File]
2360853-16-1.mol | [Molecular Weight]
449.54 |
| Chemical Properties | Back Directory | [Boiling point ]
645.4±65.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
-0.61±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC50 value of 4 nM. RBN-3143 inhibits PARP14-mediated ADP-ribosylation and stabilizes PARP14 in cell lines. RBN-3143 can be used in research of lung inflammation[1]. | [in vivo]
RBN-3143 (5 μg; intranasal administration) can improve steroid-resistant asthma mouse models[1]. | Animal Model: | Mouse of asthma models[1] | | Dosage: | 5 ug | | Administration: | Intranasal administration | | Result: | Suppressed the accumulation of alarmins TSLP, IL-33, and IL-25. |
| [IC 50]
PARP14: 4 nM (IC50); PARP10: 1600 nM (IC50); PARP15: 4200 nM (IC50); PARP4: 42700 nM (IC50); PARP3: >100000 nM (IC50); PARP2: >100000 nM (IC50); PARP1: >100000 nM (IC50) | [References]
[1] Niepel M, et, al. The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models. European Respiratory Journal?2022?60:?4642. |
|
|